Literature DB >> 28926422

Two faces of Hippo: activate or suppress the Hippo pathway in cancer.

Jingwen Cao1, Wenlong Huang.   

Abstract

The Hippo pathway has generated considerable interest in recent years because of its involvement in several key hallmarks of cancer progression and metastasis. Research on the Hippo signaling pathway in cancer has been used to determine the activity of yes-associated protein (YAP) in tumorigenesis and disease progression. Previous studies have shown that the Hippo pathway can be used as a target to inhibit YAP activity and is a viable treatment for cancer. However, more studies are required to further advance our understanding of the Hippo signaling pathway in cancer. It has been shown that knockout of serine/threonine-kinases LATS1/2 in the Hippo pathway suppresses cancer immunity in mice. In addition, suppression of the oncogene YAP could contribute toward cancer immune therapy. Therefore, regulation of Hippo signaling can be an attractive alternative strategy for cancer treatment. This review will provide a summary of currently known compounds that activate or suppress the Hippo pathway.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28926422     DOI: 10.1097/CAD.0000000000000559

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  7 in total

1.  Assessment of YAP gene polymorphisms and arsenic interaction in Mexican women with breast cancer.

Authors:  Gladis Michel-Ramirez; Rogelio Recio-Vega; R Clark Lantz; A Jay Gandolfi; Edgar Olivas-Calderon; Binh T Chau; Mary Kay Amistadi
Journal:  J Appl Toxicol       Date:  2019-10-21       Impact factor: 3.446

2.  Paris saponin VII, a Hippo pathway activator, induces autophagy and exhibits therapeutic potential against human breast cancer cells.

Authors:  Yu-Chen Xiang; Peng Peng; Xue-Wen Liu; Xin Jin; Jie Shen; Te Zhang; Liang Zhang; Fang Wan; Yu-Liang Ren; Qing-Qing Yu; Hu-Zi Zhao; Yuan Si; Ying Liu
Journal:  Acta Pharmacol Sin       Date:  2021-09-14       Impact factor: 7.169

3.  MiR-25-3p Serves as an Oncogenic MicroRNA by Downregulating the Expression of Merlin in Osteosarcoma.

Authors:  Hua-Chun Rao; Zhao-Ke Wu; Si-da Wei; Yun Jiang; Qing-Xin Guo; Jia-Wen Wang; Chang-Xian Chen; Hui-Yong Yang
Journal:  Cancer Manag Res       Date:  2020-09-24       Impact factor: 3.989

4.  circRIP2 accelerates bladder cancer progression via miR-1305/Tgf-β2/smad3 pathway.

Authors:  Yinjie Su; Weilian Feng; Juanyi Shi; Luping Chen; Jian Huang; Tianxin Lin
Journal:  Mol Cancer       Date:  2020-02-04       Impact factor: 27.401

5.  Identification of key genes and pathways in endometriosis by integrated expression profiles analysis.

Authors:  Ding Cui; Yang Liu; Junyan Ma; Kaiqing Lin; Kaihong Xu; Jun Lin
Journal:  PeerJ       Date:  2020-12-07       Impact factor: 2.984

Review 6.  Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms.

Authors:  Oleg Dobrokhotov; Mikhail Samsonov; Masahiro Sokabe; Hiroaki Hirata
Journal:  Clin Transl Med       Date:  2018-08-13

7.  CSRP2 suppresses colorectal cancer progression via p130Cas/Rac1 axis-meditated ERK, PAK, and HIPPO signaling pathways.

Authors:  Lixia Chen; Xiaoli Long; Shiyu Duan; Xunhua Liu; Jianxiong Chen; Jiawen Lan; Xuming Liu; Wenqing Huang; Jian Geng; Jun Zhou
Journal:  Theranostics       Date:  2020-09-02       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.